Critical Survey: Opus Genetics (NASDAQ:IRD) and Dyne Therapeutics (NASDAQ:DYN)

Opus Genetics (NASDAQ:IRD) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Risk & Volatility

Opus Genetics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Earnings & Valuation

This table compares Opus Genetics and Dyne Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	22.41	-$49.59 million	($1.35)	-2.85
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.33)	-7.83

Opus Genetics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Opus Genetics and Dyne Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	15	1	2.89
Dyne Therapeutics	1	2	10	2	2.87

Opus Genetics presently has a consensus price target of $10.69, indicating a potential upside of 177.72%. Dyne Therapeutics has a consensus price target of $34.42, indicating a potential upside of 31.92%. Given Opus Genetics’ stronger consensus rating and higher probable upside, research analysts plainly believe Opus Genetics is more favorable than Dyne Therapeutics.

Profitability

This table compares Opus Genetics and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Summary

Opus Genetics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.